Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
Cue Biopharma (NASDAQ: CUE) has announced a research collaboration with Dr. Michael Dustin and the University of Oxford to explore the IL-2-based CUE-100 series Immuno-STAT biologics. This partnership aims to investigate molecular mechanisms of T cell activation and modulation related to cancer treatment. The findings are expected to enhance understanding of the mechanism of action of the lead asset, CUE-101, currently in clinical trials for head and neck cancer, potentially advancing the development of new therapies for solid and hematological cancers.
Cue Biopharma (NASDAQ: CUE) announced a conference call and webcast for a business update on May 19, 2020, at 4:30 p.m. EDT. The event will provide insights into the company’s platform and pipeline advancements, alongside strategic objectives and milestones. Cue Biopharma, headquartered in Cambridge, Massachusetts, specializes in engineering injectable biologics to selectively engage T cells to combat cancer and autoimmune diseases using its proprietary Immuno-STAT™ platform. Investors can access the live event via the company’s website.